Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations?

Neurology

Volumn 71, Issue 10, 2008, Pages 714-722

  Dolk, H ^a   Jentink, J ^b   Loane, M ^a   Morris, J ^c   De Jong Van Den Berg, L T W ^b  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; VALPROIC ACID; TRANQUILIZER; TRIAZINE DERIVATIVE;

ARTICLE; CLEFT FACE; CLEFT PALATE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; EPILEPSY; FETUS RISK; FIRST TRIMESTER PREGNANCY; HUMAN; INFANT; LIVE BIRTH; MATERNAL AGE; MONOTHERAPY; POPULATION BASED CASE CONTROL STUDY; PREGNANCY OUTCOME; PREGNANCY TERMINATION; PRENATAL DIAGNOSIS; PRENATAL EXPOSURE; PRIORITY JOURNAL; REGISTER; STILLBIRTH; TERATOGENICITY; ADOLESCENT; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; CHILD; CLEFT LIP; CONFIDENCE INTERVAL; CONGENITAL DISORDER; FEMALE; HEALTH CARE PLANNING; MALE; PREGNANCY; PREGNANCY COMPLICATION; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK; RISK FACTOR;

ADOLESCENT; ANTIMANIC AGENTS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CLEFT LIP; COMMUNITY HEALTH PLANNING; CONFIDENCE INTERVALS; CONGENITAL ABNORMALITIES; EPILEPSY; FEMALE; HUMANS; MALE; ODDS RATIO; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; REGISTRIES; RETROSPECTIVE STUDIES; RISK; RISK FACTORS; TRIAZINES;

EID: 54049102073     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000316194.98475.d8     Document Type: Article

References (24)

1. Holmes LB, Wyszynski DF, Baldwin EJ, Habecker E, Glassman LH, Smith CR. Increased risk for nonsyndromic cleft palate among infants exposed to lamotrigine during pregnancy [abstract in Teratology Society platform sessions abstracts]. Birth Defects A 2006;76:318.
2. Food and Drug Administration. FDA alert September 2006. Available at: http://www.fda.gov/cder/drug/InfoSheets/HCP/lamotrigineHCP.pdf. Accessed February 22, 2007.
3. Cunnington M, Ferber S, Quartey G. International lamotrigine pregnancy registry scientific advisory committee. Epilepsia 2007;48:1207-1210.
4. Morrow J, Russel A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006;77:193-198.
5. Wide K, Winbladh B, Källén B. Major malformations in infants exposed to antiepileptic drugs in utero with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Pædiatr 2004;93: 174-176.
6. Glaxo Smith Kline International. Lamotrigine Pregnancy Registry. Interim Report 1 September 1992-31 March 2007. Issued July 2007.
7. Sabers A, Dam M, a-Rogvi-Hansen B, et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol Scand 2004;109:9-13.
8. Michell AA. Systematic identification of drugs that cause birth defects: a new opportunity. N Engl J Med 2003;349: 2556-2559.
9. Dolk H. EUROCAT: 25 years of European surveillance of congenital anomalies. Arch Dis Child Fetal Neonatal Ed 2005;90:F355-F358.
10. EUROCAT. EUROCAT Guide 1.3 and reference documents, instructions for the registration and surveillance of congenital anomalies, September 2005. Available at: http://www.eurocat.ulster.ac.uk/pdf/EUROCAT-Guide-1.3.pdf. Accessed June 20, 2007.
11. Meijer WM, Cornel MC, Dolk H, De Walle HEK, Armstrong NC, De Jong-van den Berg LTW, EUROCAT working group. The potential of the European network of congenital anomaly registers (EUROCAT) for drug safety surveillance: a descriptive study. Pharmacoepidemiol Drug Saf 2006;15:675-682.
12. ATC Index with DDDs 2003. Guidelines for ATC classification and DDD assignment 2003. Version 13. WHO Collaborating Centre for Drug Statistics Methodology.
13. Loane M, Dolk H, Morris J. Maternal age-specific risk of non-chromosomal anomalies. J Epidemiol Commun Med 2007;61 suppl 1:A9. Abstract.
14. Calzolari E, Bianchi F, Rubini M, et al. Epidemiology of cleft palate in Europe: implications for genetic research. Cleft Palate Craniofacial J 2004;41:244-249.
15. Calzolari E, Pierini A, Astolfi G, Bianchi F, Neville AJ, Rivieri F, EUROCAT Working Group. Associated anomalies in multi-malformed infants with cleft lip and palate: an epidemi-ologic study of nearly 6 million births in 23 EUROCAT registries. Am J Med Gen A 2007;143A:528-537.
16. Vajda FJE, Lander CM, Hitchcock A, et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy. J Clin Neurosci 2007;14:611-617.
17. Vajda F, Solinas C, Graham J, Hitchcock A, Eadie M. The case for lamotrigine monitoring in pregnancy. J Clin Neu-rosci 2006;13:103-104.
18. Vajda FJ, O'Brien TJ, Hitchcock A, et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of antiepileptic drugs in pregnancy. J Clin Neurosci 2004;11:854-858.
19. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000;343:1608-1614.
20. Hernandez-Diaz S, Smith CR, Wyszynski DF, Holmes LB. Risk of major malformations among infants exposed to carbamazepine during pregnancy. Birth Defects Res Part A 2007;79:351-380.
21. Khoury MJ, Adams MM, Rhodes P, Erickson JD. Monitoring for multiple malformations in the detection of epidemics of birth defects. Teratology 1987;36:345-353.
22. Bakker MK, Jentink J, Vroom F, Van den Berg PB, De Walle HEK, De Jong-van den Berg LTW. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancyrelated drugs in the Netherlands. BJOG 2006;113:559-568.
23. Holmes LB, Baldwin EJ, Smith CR, et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2008;70: 2152-2158.
24. Omtzigt JGC, Los FJ, Grobbee DE, et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992;42(suppl 5):119-125.